2. Academic Validation
  3. Novel and investigational therapies for wet and dry age-related macular degeneration

Novel and investigational therapies for wet and dry age-related macular degeneration

  • Drug Discov Today. 2022 Aug;27(8):2322-2332. doi: 10.1016/j.drudis.2022.04.013.
Aira Sarkar 1,  Srushti Jayesh Sodha 2,  Vijayabhaskarreddy Junnuthula 3,  Praveen Kolimi 4,  Sathish Dyawanapelly 5
Affiliations

Affiliations

  • 1 Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
  • 2 Department of Pharmaceutical Sciences, University of the Sciences, Philadelphia, PA 19104, USA.
  • 3 Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00790 Helsinki, Finland. Electronic address: junnuthula.vijayabhaskarreddy@helsinki.fi.
  • 4 Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, MS 38677, USA.
  • 5 Department of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai 400019, India. Electronic address: sa.dyawanapelly@ictmumbai.edu.in.
PMID: 35460893 DOI: 10.1016/j.drudis.2022.04.013
Abstract

Age-related macular degeneration (AMD) is a macular degenerative eye disease, the major cause of irreversible loss of central vision. In this review, we highlight current progress and future perspectives of novel and investigational therapeutic strategies in the drug pipeline, including anti-vascular endothelial growth factor (VEGF) agents, bispecific Antibodies, biosimilars, small molecules, gene therapy, and long-acting drug delivery strategies for both dry and wet AMD. We anticipate that biologics with dual functionalities and combined therapies with long-acting capabilities will lead the wet AMD pipeline. Sustained-release platforms also show potential. However, significant breakthroughs are yet to be made for dry AMD. The personalized approach might be well suited in the scenario of diverse genetic variations in both conditions.

Keywords

Anti-VEGF agents; Biosimilars; Bispecific antibodies; Dry AMD; Gene therapy; Port delivery system; Wet AMD.

Figures
Products